Literature DB >> 25253207

On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling.

Kenji Mizumoto, Keisuke Ejima, Taro Yamamoto, Hiroshi Nishiura1.   

Abstract

BACKGROUND &
OBJECTIVES: The present study aimed to systematically quantify the well known risk of severe dengue during secondary infection in literature and to understand how epidemiological mechanisms of enhancement during the secondary infection influence the empirically estimated risk of severe dengue by means of mathematical modeling.
METHODS: Two conditional risks of severe dengue, i.e. symptomatic illness and dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS), given secondary infection were explored based on systematically searched prospective studies. A two-strain epidemiological model was employed to simulate the transmission dynamics of dengue and to identify the relevant data gaps in empirical observations.
RESULTS: Using the variance-based weighting, the pooled relative risk (RR) of symptomatic illness during secondary infection was estimated at 9.4 [95% confidence interval (CI): 6.1-14.4], and similarly, RR of DHF/DSS was estimated to be 23.7 (95% CI: 15.3-36.9). A variation in the RR of DHF/DSS was observed among prospective studies. Using the mathematical modeling technique, we identified the duration of cross-protective immunity as an important modulator of the time-dependent behaviour of the RR of severe dengue. Different epidemiological mechanisms of enhancement during secondary infection yielded different RR of severe dengue. INTERPRETATION &
CONCLUSION: Optimal design of prospective cohort study for dengue should be considered, accounting for the time-dependence in the RR during the course of dengue epidemic. It is critical to statistically infer the duration of cross-protective immunity and clarify how the enhancement influences the epidemiological dynamics during secondary infection.

Entities:  

Mesh:

Year:  2014        PMID: 25253207

Source DB:  PubMed          Journal:  J Vector Borne Dis        ISSN: 0972-9062            Impact factor:   1.688


  13 in total

Review 1.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination.

Authors:  Stephen S Whitehead; Kanta Subbarao
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

2.  Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.

Authors:  Peter B Gilbert; Ying Huang; Michal Juraska; Zoe Moodie; Youyi Fong; Alexander Luedtke; Yingying Zhuang; Jason Shao; Lindsay N Carpp; Nicholas Jackson; Laurent Chambonneau; Alain Bouckenooghe; Betzana Zambrano; Carina Frago; Sophie Pallardy; Fernando Noriega
Journal:  Am J Trop Med Hyg       Date:  2019-07       Impact factor: 2.345

3.  Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by Aedes albopictus.

Authors:  Elizabeth A Dietrich; Yee Tsuey Ong; Janae L Stovall; Hansi Dean; Claire Y-H Huang
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

4.  No Evidence of Acute Dengue Virus Infections at a Rural Site in Western Kenya, 2011 and 2013.

Authors:  Alastair I Matheson; Ondari D Mogeni; Joshua R Lacsina; Melvin Ochieng; Allan Audi; Godfrey Bigogo; John Neatherlin; Harold S Margolis; Barry Fields; Petronella Ahenda; Judd L Walson; Joel M Montgomery
Journal:  Am J Trop Med Hyg       Date:  2020-11       Impact factor: 2.345

Review 5.  Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.

Authors:  Bruno Guy; Nicholas Jackson
Journal:  Nat Rev Microbiol       Date:  2015-12-07       Impact factor: 60.633

Review 6.  The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response.

Authors:  Jacky Flipse; Jolanda M Smit
Journal:  PLoS Negl Trop Dis       Date:  2015-06-11

7.  Mathematical models used to inform study design or surveillance systems in infectious diseases: a systematic review.

Authors:  Sereina A Herzog; Stéphanie Blaizot; Niel Hens
Journal:  BMC Infect Dis       Date:  2017-12-18       Impact factor: 3.090

8.  CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals.

Authors:  Carlos A DiazGranados; Edith Langevin; Matthew Bonaparte; Saranya Sridhar; Tifany Machabert; Gustavo Dayan; Rémi Forrat; Stephen Savarino
Journal:  Clin Infect Dis       Date:  2021-05-18       Impact factor: 9.079

9.  Dengue genetic divergence generates within-serotype antigenic variation, but serotypes dominate evolutionary dynamics.

Authors:  Sidney M Bell; Leah Katzelnick; Trevor Bedford
Journal:  Elife       Date:  2019-08-06       Impact factor: 8.713

10.  Dengue Fever and Severe Dengue in Barbados, 2008-2016.

Authors:  Kirk Osmond Douglas; Sudip Kumar Dutta; Byron Martina; Fatih Anfasa; T Alafia Samuels; Marquita Gittens-St Hilaire
Journal:  Trop Med Infect Dis       Date:  2020-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.